PT-141 Spray10mg
PT-141 Spray Canada — Nasal Spray
Melanocortin Receptor Research Peptide — Nasal Spray
PT-141, also known as bremelanotide in scientific literature, is a synthetic peptide analogue derived from melanocortin receptor research. It is developed for controlled laboratory investigation involving melanocortin receptor signaling systems.
This product is intended strictly for laboratory research use within Canada. It is not approved by Health Canada for the diagnosis, treatment, cure, or prevention of any disease. Not for human or veterinary use.
By purchasing, you confirm the material will be used solely for lawful research purposes in accordance with applicable Canadian regulations.
PT-141, also known as bremelanotide in scientific literature, is a synthetic peptide analogue derived from melanocortin receptor research. It is developed for controlled laboratory investigation involving melanocortin receptor signaling systems.
In experimental models, PT-141 is studied for its interaction with melanocortin receptors and associated neuroendocrine signaling pathways under in vitro and preclinical research conditions.
PT-141 is a synthetic melanocortin receptor agonist evaluated in research focused on melanocortin pathway signaling and neuroendocrine regulatory systems. Experimental studies examine receptor-binding dynamics and downstream signaling frameworks within controlled laboratory environments.
Preclinical and clinical research publications have explored its receptor interaction characteristics and pathway-level signaling mechanisms under structured experimental conditions.
PT-141 originated from investigations into melanocortin receptor agonists derived from α-melanocyte–stimulating hormone (α-MSH) analogues. Research into melanocortin signaling pathways led to the development of synthetic peptides designed to selectively interact with melanocortin receptor subtypes.
Subsequent studies documented its receptor-binding profile and neuroendocrine signaling properties in experimental models.
Laboratory investigations into PT-141 have focused on melanocortin receptor activation models and neuroendocrine signaling pathways. Research frameworks evaluate receptor-mediated interaction, melanocortin pathway dynamics, and regulatory signaling mechanisms under controlled in vitro and preclinical conditions.
2 of the 4 areas below are addressed directly by a paper cited on this page.
Addressed on this page by Diamond 2004. The work appeared in Int J Impot Res. Each is linked to its source record in the references below, so what was measured — and in what system — can be read rather than taken on trust.
No paper cited on this page reports on neuroendocrine. This heading marks where PT-141 Spray is discussed in the category rather than a question the cited literature answers, and it is worth knowing which of these areas has work behind it and which does not.
No paper cited on this page reports on analogue. This heading marks where PT-141 Spray is discussed in the category rather than a question the cited literature answers, and it is worth knowing which of these areas has work behind it and which does not.
Addressed on this page by Diamond 2004. The work appeared in Int J Impot Res. Each is linked to its source record in the references below, so what was measured — and in what system — can be read rather than taken on trust.
The references section of this page cites 4 primary papers published between 2004 and 2025 — a limited but non-trivial record. Every citation is linked to its PubMed or DOI record so it can be read rather than taken on trust, and the summaries above describe what those papers report rather than what the compound is claimed to do.
Research compounds attract claims that outrun their evidence. Below are the ones most often encountered for PT-141 Spray, set against what the papers cited on this page actually report. Where the record is thin or contested, that is stated rather than smoothed over.
PT-141 Spray is also referred to as bremelanotide, PT141.
Approved prescription medicines containing the same active ingredient are sold under the brand name Vyleesi. The material supplied here is not those products and is not interchangeable with them. Those are regulated pharmaceuticals manufactured to a licensed specification and dispensed under medical supervision. This is a research compound, and what is published for it is its measured purity and content per lot.
PT-141 Spray is commonly described online in connection with increased libido and sexual function. In the research literature the same compound is filed under melanocortin receptor activation models, neuroendocrine signaling pathway studies and α-MSH analogue research frameworks.
Of the 4 papers cited on this page, published between 2004 and 2025, 3 report work in human participants — Kingsberg 2019, Clayton 2016 and Diamond 2004. Human data for a molecule is not the same as evidence for material supplied as a research compound: published trials use pharmaceutical-grade product under medical supervision at defined doses. What is established for the material sold here is its measured purity and content per lot.
Nothing above is a statement of what this material does. It is a summary of what has been published and what has not. Eppix Labs supplies research materials only and provides no dosing, administration or protocol guidance.
Verification for PT-141 Spray is per lot, not per product. The current 10mg lot PT-CA-26A-01 returned 99.864% purity, 11.86 mg measured, 118.6% of the labelled 10 mg, assayed by Janoshik. Those figures are the laboratory's, published in full rather than reduced to a badge.
The lot code printed on the vial matches the code on the certificate for PT-141 Spray. Matching the two is what confirms the unit in hand came from the batch that was tested — a certificate not tied to a lot code proves nothing about any particular unit.
Researchers who buy PT-141 Spray in Canada through Eppix Labs receive the lot described by the certificate above: the code printed on the vial label is the code on the certificate, and both are searchable on the batch verification page.
PT-141 Spray ships as a prepared solution rather than as lyophilized powder, so it is already past the point at which a powder would be reconstituted. That shortens handling but tightens storage: a compound in solution is less stable than the same compound dry, and refrigeration from arrival onward is the relevant control.
The stability window for a solution is shorter than the shelf life of a sealed lyophilized vial of the same compound. Records for laboratory work in this format should note the date the unit was opened, not only the date it was received.
Vials may appear empty on arrival. Lyophilized material collects at the base of the vial and is often not visible until the vial is inspected under direct light.
No. Eppix Labs products are supplied exclusively for laboratory research. We do not provide dosing, administration, or usage guidance.
Each vial contains 10mg of lyophilized PT-141. Independent third-party testing verifies purity, identity, and net content per batch.
The vial contains only the peptide preparation. Any laboratory materials required for experimental procedures must be sourced separately.
Duration depends entirely on research protocol, storage conditions, and laboratory application.
Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstet Gynecol 134(5):899–908.
PubMedBremelanotide for female sexual dysfunctions in premenopausal women: a randomized, placebo-controlled dose-finding trial. Womens Health (Lond) 12(3):325–337.
PubMedDouble-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction. Int J Impot Res 16(1):51–59.
PubMedFemale Syrian hamster analyses of bremelanotide, a US FDA approved drug for the treatment of female hypoactive sexual desire disorder.
PubMedRelated
Eppix Flash Sale −30%Peptides
Triple GIP / GLP-1 / Glucagon Agonist · 10, 20, 40 & 120 mg Retatrutide is a synthetic peptide developed for controlled laboratory research involving multi-receptor signaling systems. It is structurally designed to interact with GLP-1, GIP, and glucagon receptor pathways within experimental environments.
RETA-CA-26F-1099.637%
11.76 mg / 10 mg
$41.96$59.95CAD
Flash sale ends in
Eppix Flash Sale −30%Peptides
Dual GIP / GLP-1 Agonist · 10, 30 & 65 mg Tirzepatide is a synthetic peptide developed for controlled laboratory research involving dual incretin receptor signaling systems. It is structurally designed to interact with GLP-1 and GIP receptor pathways within experimental environments.
TIRZ-CA-26G-1099.634%
11.42 mg / 10 mg
$24.46$34.95CAD
Flash sale ends in
Eppix Flash Sale −30%Peptides
GLP-1 Receptor Agonist · 10 mg Semaglutide is a synthetic analogue of glucagon-like peptide-1 (GLP-1), a naturally occurring incretin hormone involved in glucose-dependent signaling. It is developed for controlled laboratory investigation within regulated experimental environments.
10 mgSEMA-CA-26F-1099.504%
11.27 mg / 10 mg
$38.46$54.95CAD
Flash sale ends in
Eppix Flash Sale −30%Peptides
Selective Amylin Agonist (LY3841136) · 10 mg This product is supplied as eloralintide (LY3841136), a long-acting, selective amylin receptor agonist studied in research on metabolic and body-weight regulation.
10 mgELOR-CA-26G-1099.810%
12.42 mg / 10 mg
$101.46$144.95CAD
Flash sale ends in
